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INTRODUCTION
The complications of diabetes represent the main volume in dis-
ability, reduced life expectancy, and economic cost associated 
with diabetes.1 The most common and debilitating complication 
of diabetes is diabetic peripheral neuropathy (DPN), which affects 
60–70% of patients and causes frequent hospitalization in diabe-
tes.2 Sensorimotor polyneuropathy is the most common form of 
DPN and can affect all types of nerve fibers. Abnormal sensory per-
ception in diabetic patients includes loss of pain and temperature 
sensation, and burning skin and tenderness, initially affecting the 
feet and lower legs and later hands and arms. In more advanced 
stages, foot ulcers and neuropathic deformities may develop, even-
tually resulting in 40% of nontraumatic limb amputations. Axonal 
degeneration, nerve fiber loss, segmental demyelination, and 
remyelination are characteristic pathological features of human 
DPN.3 Although intensive insulin therapy to control blood glucose 
reduces the incidence of new clinically detected neuropathy, dia-
betic patients still develop DPN.
Gene therapy strategies for treatment of chronic pain, genetic 
and acquired peripheral neuropathies like DPN, or accelerating 
peripheral nerve regeneration could be envisaged if efficient gene 
transfer to the peripheral nervous system (PNS) would be achieved. 
Viral vectors offer the possibility to specifically target different cell 
types in the PNS. We and others have demonstrated transduction 
of mouse and human Schwann cells in vitro4 and in vivo in animal 
models of peripheral nerve trauma.5,6 Herpes simplex virus–based 
vectors were shown to efficiently transduce sensory neurons when 
injected subcutaneously in animal models, which has lead to the 
initiation of a phase 1 clinical trial for pain treatment (for review, 
see ref. 7). Several serotypes of adeno-associated viruses (AAV) also 
infect sensory neurons in the dorsal root ganglia (DRG) through 
direct administration into the cerebrospinal fluid (CSF), via retro-
grade transport or by intravenous administration.8–12
Among the different AAV serotypes tested, AAVrh10, a nonhuman 
primate serotype, was proven to efficiently transduce neurons in the 
brain after intracranial administration, enabling a widespread diffu-
sion, similar to AAV1 or AAV9.13,14 Moreover, intravenous administra-
tion of AAVrh10 in neonatal mice crosses the blood–brain barrier 
and drives one of the most efficient transduction to the spinal cord 
and central nervous system compared to other AAV serotypes.15,16
With the aim to study if AAVrh10 vector is capable to efficiently 
deliver a therapeutic gene to sensory and motor neurons, we tested 
the biodistribution of this vector and compared it with AAV1, AAV2, 
and AAV8, following intraneural and intrathecal administration in 
adult mice. Here, we demonstrate that after lumbar delivery of the 
vectors into the CSF, the AAV vectors were widely distributed to 
Received 6 November 2013; revised; accepted 7 November 2013;
2329-0501
7








© 2014 The American Society of Gene & Cell Therapy
Intrathecal AAVrh10 for gene therapy for diabetic neuropathy
J Homs et al.
Different adeno-associated virus (AAV) serotypes efficiently transduce neurons from central and peripheral nervous systems 
through various administration routes. Direct administration of the vectors to the cerebrospinal fluid (CSF) could be an efficient and 
safe strategy. Here, we show that lumbar puncture of a nonhuman AAV leads to wide and stable distribution of the vector along the 
spinal cord in adult mice. AAVrh10 efficiently and specifically infects neurons, both in dorsal root ganglia (60% total sensory neu-
rons) and in the spinal cord (up to one-third of α-motor neurons). As a proof of concept, we demonstrate the efficacy of AAVrh10 
in a mouse model of diabetic neuropathy, in which intrathecal delivery of the vector coding for insulin-like growth factor (IGF-I) 
favored the release of the therapeutic protein into the CSF through its expression by sensory and motor neurons. IGF-I–treated 
diabetic animals showed increased vascular endothelial growth factor expression, activation of Akt/PI3K pathway, and stimulated 
nerve regeneration and myelination in injured limbs. Moreover, we achieved restoration of nerve conduction velocities in both 
sensory and motor nerves by AAVrh10, whereas we reached only sensory nerve improvement with AAV1. Our results indicate that 
intrathecal injection of AAVrh10 is a promising tool to design gene therapy approaches for sensorimotor diseases.
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the entire spinal cord, from lumbar to cervical segments. AAVrh10 
efficiently infected neurons, both in DRG (near 60% of total sensory 
neurons) and in the spinal cord (up to 30% of motoneurons), while 
AAV1 was only able to transduce sensory neurons in the DRG. Finally, 
as a proof of concept, we demonstrated the efficiency of AAVrh10 in 
a mouse model of experimental diabetes, in which intrathecal deliv-
ery of AAVrh10 coding for insulin-like growth factor (IGF-I) was able 
to release the therapeutic protein into the CSF. In sensory and motor 
neurons of diabetic animals overexpressing IGF-I, we detected 
overexpression of vascular endothelial growth factor (VEGF) and 
activation of Akt/PI3K pathway as well as nerve regeneration and 
myelination in injured limbs. Moreover, we found increased nerve 
conduction velocity (NCV) in both sensory and motor nerves by 
AAVrh10-driven expression of IGF-I compared to green fluorescent 
protein (GFP)–treated mice, whereas only sensory nerve improve-
ment was found using AAV1. These data demonstrate the potential 
of AAVrh10 for sensorimotor gene therapy.
ReSUlTS
AAVrh10 efficiently transduces sensory neurons in DRG
As a first approach to test AAVrh10 efficacy transducing sensory 
neurons, we delivered 1 × 1011 viral genomes (vg) into the CSF by 
lumbar puncture in the subarachnoid space, and it was compared 
to AAV1, AAV2, and AAV8. Animals were euthanized 3 weeks after 
administration, DRG sectioned, and GFP was quantified by direct 
fluorescent imaging. No transduction was obtained using AAV8, 
very small numbers of GFP-positive cells were counted with AAV2 
(not shown), and the highest levels were achieved using AAV1 or 
AAVrh10. AAVrh10 tropism was characterized after intrathecal 
administration in the lumbar area by immunohistochemistry to spe-
cific neuronal markers. We quantified 13 ± 1.3% of transduced large 
neurons (NF-200 positive, Figure 1a–c) and 60 ± 3.2% of peripherin 
immunoreactivity (Figure 1d–f), showing GFP expression in lum-
bar ganglia (n = 3). Peripherin-positive neurons can be divided 
in calcitonin gene-related peptide or Ib4-positive nerons. Here, 
29 ± 2.3% of calcitonin gene-related peptide positive colocalized 
with GFP (Figure 1g–i) and 11 ± 1.6% of IB4 neurons were also GFP 
positive (Figure 1j–l; n = 3). AAV1 transduced both large and small 
neurons but to a lower extent, and numbers were not quantified 
(Supplementary Figure S1a–f ).
Although viral vectors were administered between the third and 
fourth lumbar vertebrae, once delivered in the intrathecal space, 
the virus was diluted in the CSF and could reach more proximal seg-
ments. Thus, we quantified GFP-expressing sensory neurons in lum-
bar, thoracic, and cervical DRG at week 1, 3, and 6 after virus adminis-
tration (Figure 2a; Supplementary Figure S2). For AAV1, we detected 
stable transduction up to 6 weeks after injection only in lumbar DRG 
(Supplementary Figure S2; n = 3/time point). For AAVrh10, the high-
est level of transduction in the DRG was achieved at the injection 
area, that is the lumbar ganglia, where 56.9 ± 14.8% (n = 3 animals) 
of total DRG neurons showed GFP expression at 6 weeks (Figure 2a). 
Moderately lower levels of expression, although not significantly 
different, were quantified in the cervical area (36.1 ± 13.5%; n = 3 
animals). However, in the thoracic segments, significantly lower 
numbers were detected, particularly 1 and 3 weeks after treatment, 
a phenomenon already described for AAV6.10 AAVrh10-driven GFP 
expression was also evident along the axons of the transduced ani-
mals. Transversal sections of sciatic nerves showed around 50% of 
nerve fibers expressing GFP (Supplementary Figure S3a; n = 3 ani-
mals) that probably correspond to axons from infected nuclear bod-
ies projecting to the hind limb. Moreover, direct intrasciatic injection 
of 9 × 109 viral genomes of AAVrh10 coding for GFP targeted exclu-
sively neurons and demonstrated its ability to be retrogradely trans-
ported to the neuronal bodies in the DRG (Supplementary Figure 
S3b; n = animals), as we have previously reported for AAV1 and 
AAV2 (ref. 6).
Intrathecal administration of AAVrh10 allows motor neuron 
transduction
Transduction of motor neuron after intrathecal administration of 
AAV9 was reported previously in mice, pigs, and nonhuman pri-
mates.17–20 In lumbar spinal cord sections of AAVrh10-injected ani-
mals, we also observed widespread GFP expression in both dorsal 
and ventral areas (Supplementary Figure S4). In the white matter, 
we observed punctate signals, corresponding to the dorsal and ven-
tral afferences entering the spinal cord (Supplementary Figure S4), 
but most importantly, at the dorsal and ventral gray matter, we also 
found cell bodies expressing GFP with a neuronal pattern (Figure 3). 
Immunohistochemical analysis with selective markers allowed 
us to  characterize the transduced cell types. We did not detect 
 transduction of astrocytes (glial fibrillary acidic protein– positive 
cells; Figure  3d–f,n) and microglia (Iba1 immunoreactivity; Figure 
3j–l,p) and only very few oligodendrocytes (APC1-positive cells; 
Figure 3g–i,o and arrowhead in i). GFP-positive cell bodies colocal-
ized mainly with choline acetyltransferase immunostaining, a specific 
Figure 1 AAVrh10 transduction of dorsal root ganglia. (a, d, g, j) DRG 
sections from animals transduced with AAVrh10-GFP and euthanized 
at 3 weeks. (b, e, h, k) Immunohistochemistry with broad and specific 
markers of sensory neurons: (b) NF-200, (e) peripherin, (h) CGRP, and 
(k) IB4. GFP-positive sensory neurons merged with specific sensory 
markers (arrows, c, f, i, l). Scale bar = 81 µm. AAV, adeno-associated virus; 
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marker for cholinergic neurons (Figure  3a–c,m). We observed the 
strongest GFP signal in somatic motoneurons located in the ventral 
horn, of either big (>20 µm) or small size (<20 µm), and in either the 
medial or the lateral motor columns that send their axons to axial and 
limb muscles, respectively. Minor expression was detected in auto-
nomic neurons located in the intermediolateral column in lamina VII 
at thoracic levels. We quantified the number of neurons in the ventral 
area of the spinal cord along the different spinal segments (cervical, 
thoracic, and lumbar; Figure 2b; n = 3 animals). At 3 weeks, we found 
near 40 neurons per section in the lumbar segments and around 
20 neuronal somas in the thoracic and cervical segments without 
using immunohistochemistry against GFP. Importantly, one-third of 
α-motoneurons were transduced in all segments analyzed (Figure 2c). 
This demonstrates that AAVrh10-driven expression is stable over this 
period of time and that viruses diluted in the CSF were able to trans-
duce sensory and spinal motor neurons in all the subdivisions of the 
spinal cord. Small interneurons expressing GFP as well as dorsal horn 
neurons were also observed, mainly in the lumbar region. Contrary to 
AAVrh10, AAV1-injected animals did not show GFP expression in the 
spinal cord (data not shown). In addition, we did not detect transduc-
tion of the meninges with any of the viruses used.
Motor and sensory neuron overexpression of IGF-I in a mouse 
model of DPN
As a proof of principle to test for the efficacy of AAVrh10 in treating 
diseases affecting both sensory and motor neurons, we used a mouse 
model of diabetic neuropathy by combining induction of diabetes by 
multiple low doses of streptozotocin with sciatic nerve crush. Four 
weeks after initiation of diabetes, male CD-1 mice were intrathecally 
injected with 1 × 1011 viral genomes of AAVrh10 or AAV1 coding for 
either IGF-I or GFP and submitted to sciatic nerve lesion on one leg to 
evaluate the regeneration delay that has been described in diabetic 
mice.21,22 Electrophysiological studies were performed at 3 and 4 
weeks postcrush (7 and 8 weeks after streptozotocin treatment) after 
which the animals were euthanized and samples processed for molec-
ular analyses. Animals were monitored for weight and glycemia every 
2 weeks (Supplementary Figure S5). All mice showed established 
hyperglycemia on the day of surgery without significant changes 
along the duration of the experiment (Supplementary Figure S5b,d). 
No statistically significant differences were observed between the 
four groups in body weight (Supplementary Figure S5a,c; Student’s 
Figure 2 Quantification of GFP-positive sensory and motor neurons 
transduced by intrathecal AAVrh10. (a) Percentage of GFP-positive DRG 
neurons at different levels (lumbar, thoracic, and cervical) at 1, 3, and 6 
weeks postinjection. (b) Number of GFP-positive neurons per section 
quantified at different segments of the ventral spinal cord (lumbar, 
thoracic, and cervical) after Nissl-positive colocalization. (c) Percentage 
of GFP-positive α-motoneurons quantified from b by size (>20 µm). 
Values are represented as the mean ± SEM (n = 3/group and time point). 
Statistically significant differences were observed by two-way ANOVA 
and Bonferroni post hoc tests in a (P < 0.05) at week 3 for lumbar versus 
thoracic and cervical numbers but not in b or c. AAV, adeno-associated 
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c Figure 3 Tropism characterization of AAVrh10 in spinal cord after 
intrathecal administration of the vector. (a, d, g, j) GFP-transduced 
cells in the ventral horn of lumbar spinal cord (given in green). (b, e, 
h, k) Immunohistochemical analysis of spinal cord cross-sections with 
specific cell markers, (b) ChAT for motoneurons; (e) GFAP for astrocytes; 
(h) APC1 for oligodendrocytes; and (k) Iba1 for microglia (all given in red). 
(c) Merged images (c, f, i, l) showed restricted colocalization only 
between GFP and ChAT (m), except for one cell in i (arrowhead) 
colocalizing between APC1 and GFP. a–l, bar = 70 µm. Magnified merged 
images (m, n, o, p; scale bar = 31 µm). AAV, adeno-associated virus; ChAT, 
choline acetyltransferase; DRG, dorsal root ganglia; GFAP, glial fibrillary 
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t-test, n = 10 for GFP and 15 for IGF-I in AAVrh10-treated groups; n = 7 
for GFP and 17 for IGF-I in AAV1-treated groups).
Electrophysiological studies showed evidences of peripheral neu-
ropathy in the left intact hind limb of the diabetic mice that had signif-
icantly reduced motor and sensory NCV with respect to values of con-
trol mice. AAV vector injection did not induce further deterioration, 
and AAV-GFP mice had similar neuropathy as control noninjected 
diabetic mice (Table 1), despite variability between groups. Mice that 
received a vector for IGF-I expression showed less marked deteriora-
tion of peripheral nerve function during the month of follow-up that 
corresponding AAV-GFP mice. Mice with AAV1-IGF-I had significantly 
higher distal sensory NCV, whereas mice injected with AAVrh10-IGF-I 
had significantly higher amplitude of the sensory compound nerve 
action potential and proximal sensory NCV compared with their cor-
responding controls with vector encoding GFP (Table 1).
Regarding the regeneration capability, all the diabetic mice had 
slower rate of regeneration and reinnervation of motor and sensory 
targets after sciatic nerve lesion than control mice, as previously 
reported.22 Administration of the AAV1-IGF-I did not produce any 
improvement of the regenerative capability evaluated by electro-
physiological and functional methods. In contrast, mice injected 
with AAVrh10-IGF-I showed significantly higher motor and sensory 
NCV at 31 days postinjury (Table 2), suggestive of faster regenera-
tion and maturation of the injured axons.
Four weeks after AAV injection and 8 weeks after induction of dia-
betes, animals were euthanized. IGF-I expression was demonstrated 
by immunohistochemistry in lumbar DRG and spinal cord in both 
AAV1- and AAVrh10-injected animals (Figure 4a,d, respectively). IGF-I 
immunohistochemistry in DRG differs from GFP expression shown in 
Figure 1 because IGF-I is a secreted protein, and as IGF-I receptor is also 
expressed in DRG cells,23 it can be uptaken by other nontransduced 
neighboring cells, showing the global image of IGF-I signal in the DRG. 
Quantitative real-time PCR from lumbar DRG and ventral horn spinal 
cord also showed significant increase of IGF-I mRNA with both vec-
tors compared to GFP (Figure 4b; n = 5–7/group; **P < 0.01 and ***P < 
0.005 by one-way analysis of variance and Tukey’s multiple comparison 
test), correlating with immunohistochemistry images. Moreover, levels 
of IGF-I were also detected by enzyme-linked immunosorbent assay in 
the CSF of treated animals at the time of sacrifice, particularly for those 
injected with AAVrh10 (Figure 4c; n = 3/group; *P < 0.05 by Student’s 
t-test). AAV1-injected animals also showed increased IGF-I in CSF but not 
statistically significant from GFP-treated animals (Figure 4c). Increased 
IGF-I in sensory neurons probably activated Akt signaling pathway, as 
shown by phosphorylation of Akt compared to total Akt protein levels 
in AAVrh10 IGF-I and but not in GFP-injected mice (Figure 5a). IGF-I is 
capable to activate different signaling pathways and to promote cell 
survival as well as to regulate the expression of different trophic factors, 
VEGF being one among them. VEGF has been shown to be essential 
for neuronal survival, and its secretion and mRNA expression in many 
tissues is being induced by IGF-I. In Figure 5b, we show a significant 
increase in VEGF protein in lumbar DRG of IGF-I–injected animals, com-
pared to GFP-injected mice. On the other hand, growth associated pro-
tein 43 (GAP-43) is overexpressed by neurons in the process of regen-
eration, and it is located in the growth cones of regenerating axons. We 
analyzed GAP-43 in regenerating sciatic nerves from animals injected 
with vectors expressing IGF-I or GFP at the time of injury. We detected 
a significant increase in GAP-43 mRNA in DRG and GAP-43 protein in 
sciatic nerve, 4 weeks after AAVrh10 IGF-I treatment (Figure 6a,b, respec-
tively), correlating with the electrophysiological results and confirming 
a positive effect of IGF-I in the regeneration of injured nerves in diabetes. 
Levels of GAP-43 mRNA were also found increased in sciatic nerves of 
AAV1-injected animals but at lower levels than that in AAVrh10-injected 
animals. AAV1-mediated GAP-43 protein was not significantly increased 
in these animals (Supplementary Figure S6a,b).
Schwann cells play an important role in the regeneration process 
of PNS after injury. In this regard, Schwann cell survival, prolifera-
tion, motility, and myelination are crucial for a proper regeneration 
of the injured nerve, and all these processes can be promoted by 
IGF-I. We detected increased levels of PNS myelin proteins: myelin 
protein zero (P0), PMP22, myelin basic protein, and myelin-asso-
ciated glycoprotein 4 weeks after injury in IGF-I–treated sciatic 
nerves (Figure 6c,d; Supplementary Figure S6c,d). Quantitative 
PCR of myelin proteins showed strongly increased mRNA levels in 
AAVrh10-injected animals and a similar tendency for AAV1-treated 
mice, although with lower levels. Myelin protein zero, accounting 
for 50% of PNS myelin proteins, was ten times enhanced in AAVrh10 
IGF-I–injected animals and only four times in AAV1-injected mice, 
both of them being statistically significant (P < 0.05).
DISCUSSION
The goal of this study was to analyze the potential of AAV vectors 
for treating DPN. Even if DPN widely affects the PNS, restricted 
administration to the target tissue may be crucial, avoiding the use 
Table 1 Results of electrophysiological tests performed in the intact hindlimb of diabetic mice at 7 and 8 weeks after induction of diabetes 
(3 and 4 weeks after intrathecal injection of viral vector in the AAV groups)
Treatment Control (n = 10) AAV1-GFP (n = 10) AAV1-IGF-I (n = 21) AAVrh10-GFP (n = 7) AAVrh10-IGF-I (n = 15)
Week diabetes 7 8 7 8 7 8 7 8 7 8
Plantar muscle
  CMAP (mV) 6.7 ± 0.4 6.5 ± 0.4 6.8 ± 0.4 6.3 ± 0.4 6.4 ± 0.3 6.3 ± 0.5 6.6 ± 0.9 6.3 ± 0.6 6.3 ± 0.3 5.9 ± 0.3
  MNCV (m/s) 36.4 ± 1.2 34.8 ± 1.1 33.1 ± 0.8c 34.1 ± 1.1 38.8 ± 1.8 36.5 ± 0.6 36.7 ± 2.2 34.7 ± 2.1 41.3 ± 2.2 42.3 ± 2.2c
Digital nerve
  CNAP (µV) 29.4 ± 2.4 24.1 ± 1.1 31.9 ± 3.5 26.6 ± 2.2 32.2 ± 2.3 33.5 ± 2.7c 29.2 ± 3.0 20.0 ± 3.1 36.3 ± 3.0 31.2 ± 2.6b,c
  SNCVp (m/s) 36.5 ± 0.9 34.7 ± 0.9 36.9 ± 1.9 36.0 ± 1.8 39.9 ± 1.1 37.2 ± 1.0 42.6 ± 2.8c 39.2 ± 1.7c 44.1 ± 2.8c 46.7 ± 2.0b,c
  SNCVd (m/s) 29.2 ± 0.7 25.9 ± 0.7 29.1 ± 0.7 24.2 ± 0.8 32.0 ± 0.6a 28.7 ± 0.6a 28.1 ± 1.4 24.8 ± 0.9 28.6 ± 0.9 26.0 ± 0.6
Data are expressed as mean ± SEM. All CMAP and CNAP amplitudes are given for nerve stimulation at the sciatic notch.
CMAP, compound muscle action potential; CNAP, compound nerve action potential; MNCV, motor nerve conduction velocity; SNCV, sensory nerve conduction 
velocity; -d: distal nerve segment; -p: proximal nerve segment.
P < 0.05 versus aAAV1-GFP. bAAVrh10-GFP. cControl at the same time of follow-up. ANOVA with Bonferroni post hoc tests.
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of large doses of vector and the chance of expression of recom-
binant proteins in undesired tissues, leading to development of 
secondary effects or stimulation of the immune response against 
the virus or the therapeutic protein.24,25 For this reason, we deliv-
ered AAV1 and AAVrh10 vectors to the CSF by lumbar puncture, a 
minimally invasive route that can be potentially performed in an 
outpatient setting, so to allow reaching sensory and motor neu-
rons with minor exposure of peripheral tissues. Broad delivery to 
the PNS by targeting sensory and/or motor neurons is required 
to treat neuropathic pain, nerve trauma, or diseases-like DPN, 
Charcot–Marie–Tooth, amyotrophic lateral sclerosis, or spinal mus-
cular atrophy.26–28 Here, we demonstrate that AAVrh10 delivered by 
Table 2 Results of electrophysiological tests performed in the right hindlimb of diabetic ICR mice at 7 and 8 weeks after induction of diabetes, 
and 3 and 4 weeks after sciatic nerve crush (w.p.i.) and intrathecal injection of viral vector
Treatment AAV1-GFP (n = 9) AAV1-IGF-I (n = 21) AAVrh10-GFP (n = 7) AAVrh10-IGF-I (n = 15)
w.p.i. 3 4 3 4 3 4 3 4
Ant tibialis muscle
  CMAP (mV) 12.5 ± 1.5 18.2 ± 1.8 12.6 ± 1.0 21.2 ± 1.1 14.0 ± 1.0 23.1 ± 1.6 14.7 ± 1.6 23.6 ± 2.5
Plantar muscle
  CMAP (mV) 0.54 ± 0.17 1.29 ± 0.34 0.41 ± 0.05 1.24 ± 0.21 0.63 ± 0.12 1.11 ± 0.32 0.64 ± 0.12 1.18 ± 0.18
  MNCV (m/s) 11.3 ± 1.2 15.4 ± 0.8 11.3 ± 1.0 17.1 ± 1.1 10.4 ± 2.1 13.7 ± 0.7 16.1 ± 1.3a 18.8 ± 1.2a
Digital nerve
  CNAP (µV) 0.78 ± 0.44 3.43 ± 1.34 0.52 ± 0.29 3.10 ± 0.76 0 ± 0 2.60 ± 1.08 0.92 ± 0.64 3.67 ± 0.78
  SNCVp (m/s) 15.3 ± 3.9 15.5 ± 1.0 16.4 ± 5.0 15.4 ± 1.4 — 21.2 ± 6.1 — 23.8 ± 1.3
  SNCVd (m/s) 3.7 ± 0.5 7.3 ± 0.5 4.2 ± 0.8 7.4 ± 0.5 — 6.0 ± 0.7 — 10.0 ± 1.9a
Pinprick score 3.3 ± 0.5 5.8 ± 0.7 2.7 ± 0.3 5.3 ± 0.4 1.0 ± 0.0 4.0 ± 0.5 1.0 ± 0.2 5.1 ± 0.5
Data are expressed as mean ± SEM. All CMAP and CNAP amplitudes are given for nerve stimulation at the sciatic notch.
P < 0.05 versus aAAVrh10-GFP at the same time of follow-up. ANOVA with Bonferroni post hoc tests.
ANOVA, analysis of variance; CMAP, compound muscle action potential; CNAP, compound nerve action potential; MNCV,  motor nerve conduction velocity; SNCV, 
sensory nerve conduction velocity; -d: distal nerve segment; -p: proximal nerve segment; w.p.i.: weeks post infection.
Figure 4 IGF-I expression driven by AAV1 or AAVrh10 is detected in sensory and motor neurons and secreted to the CSF of diabetic mice. IGF-I expression 
is demonstrated 4 weeks after intrathecal administration of AAV vectors. (a) IGF-I immunohistochemistry in DRG and (d) ventral spinal cord sections 
from the lumbar area. Confocal microscopy detected increased IGF-I staining in sensory and motor neuron-like morphology in mice injected with 
AAV1-IGF-I and AAVrh10 IGF-I compared to control animals injected AAV coding for GFP. Images were obtained sequentially under identical scanning 
conditions for each independent channel (red channel: IGF-I; blue channel: TO-PRO-3 to counterstain nuclei; n = 2). (b) Quantitative PCR from lumbar 
DRG and ventral horn of spinal cord showed significant increase of IGF-I with both vectors compared to GFP (one-way ANOVA and Tukey’s multiple 
comparison test; **P < 0.01; ***P < 0.005; n = 5–7/group). (c) IGF-I ELISA from CSF of treated animals obtained at the time of sacrifice (n = 3/group). 
Statistically significant numbers were obtained for AAVrh10-treated animals but not with AAV1, compared to nontreated control animals (Student’s 
t-test, *P < 0.05). a, bar = 160 µm d, bar = 73 µm. AAV, adeno-associated virus; ANOVA, analysis of variance; CSF, cerebrospinal fluid; ELISA, enzyme-linked 









































































Intrathecal AAVrh10 for gene therapy for diabetic neuropathy
J Homs et al
Molecular Therapy — Methods & Clinical Development (2014) 7 © 2014 The American Society of Gene & Cell Therapy
lumbar puncture infects both sensory and motor neurons along 
the different segments of the spinal cord, with only significant dif-
ferences in the relative percentage of neurons transduced between 
lumbar and thoracic DRG, but no differences were found between 
motoneurons or even between lumbar and cervical DRG. With only 
10 µl of viruses, we achieved up to 60% of sensory neurons and 
30% of motoneurons transduced. Moreover, in this work, we have 
used single-strand AAV as a platform, reported to be 20-fold less 
efficient compared to self-complementary AAVs, and we did not 
use immunohistochemistry to quantify GFP expression in trans-
duced cells to avoid overestimation due to background, so we 
may have, in addition, ten times lower sensitivity when quantifying 
transduction levels.
Studies in larger animals are important to evaluate the potential 
of the therapeutic strategy. As a matter of fact, intramuscular AAV6 
in nonhuman primates could target 50% motoneurons in 1-cm-long 
lumbar spinal cord segment.29 Moreover, intravenous AAV9 was able 
to transduce motoneurons in adult cats up to 15% from lumbar to 
cervical segments, although peripheral tissues, including testis, were 
also labeled.30 Recently, intrathecal administration of AAV9 in pigs 
and nonhuman primates demonstrated the capability of transduc-
ing sensory and motor neurons. However, most of transduced cells 
were astrocytes.20,31,32 This is also in accordance with the preferential 
transduction of astrocytes after intravenous administration of this 
vector in adult mice.33 Other serotypes, like AAV7, seem to be as effi-
cient as AAV9 after intracisterna injection and targets both neurons 
and astrocytes.19 Herein, we demonstrate AAVrh10-specific tropism 
for neurons in the spinal cord and DRG, similar to what was reported 
for the central nervous system,14 but not for glial cells as found for 
AAV7 and AAV9, which may be an advantage because restricting cell 
type infection may decrease immunological response, although this 
needs to be analyzed.20 In this regard, a high percentage of humans 
are seropositive for different AAV serotypes. In adults, anti-AAV2 anti-
bodies are the most prevalent (up to 70% of healthy humans), fol-
lowed by serotypes AAV5, AAV9, and AAV8.34 Using a nonhuman AAV 
serotype in human gene therapy trials may have additional advan-
tages compared to human serotypes like AAV9, since patients may 
not be preimmunized against this serotype, although cross-reaction 
between AAVrh10 and human AAV serotypes needs to be quantified.
As a proof of principle, we administered IGF-I as therapeutic gene 
in the mouse model of DPN. IGF-I provides trophic support to neu-
rons of peripheral and central nervous systems. Through its tyrosine 
kinase receptor, IGF-I upregulates other neurotrophic factors includ-
ing hypoxic-inducible factor 1α and VEGF.35 Schwann cells express 
IGF-I receptors, and their activation promotes myelination36 and pro-
tects Schwann cell dysfunction induced by high glucose in vitro.37 
Importantly, intrathecal daily delivery of IGF-I through an infusion 
pump in diabetic rats reversed slowing of motor and sensory con-
duction velocity as well as atrophy of myelinated sensory axons in 
peripheral nerve.38 In fact, the therapeutic effect of growth factors 
was demonstrated for DPN by promoting neuronal survival, stimulat-
ing repair of peripheral nerve injury, or inducing nerve regeneration 
under diabetic conditions (for review, see ref. 39). For that reason, 
clinical trials using nerve growth factor, brain-derived neurotrophic 
factor, VEGF, and C-peptide were proposed, although without signifi-
cant benefit so far.40–43 Delivering factors continuously through gene 
therapy vectors may considerably improve the efficiency of these tri-
als. Indeed, AAVrh10 vector may enable the long-term expression in 
sensory and motor neurons along the spinal cord without the risk of 
insertional mutagenesis.44 Delivering nonsecreted proteins through 
this method could be an additional challenge since only those neu-
rons expressing the transgene will be corrected.
Unfortunately, animal models of diabetes do not reach the 
severity of human diabetic neuropathy. Animal nerves usually 
show relatively mild neurophysiological deficits and minor mor-
phometric changes.45,46 The lack of degenerative neuropathy in 
diabetic rodent models seems to be a consequence of the short 
life span of rodents or the physically shorter axons. Degenerative 
neuropathy is minimal even in larger animals like dogs or primates, 
with the exception of cats.47 For this reason, we combined diabe-
tes with nerve injury, because it is demonstrated that PNS regen-
eration is impaired in diabetic patients and animal models.21,22 
The results presented here demonstrate that IGF-I delivery using 
AAVrh10 achieves higher transduction to sensory neurons and, 
more importantly, to motoneurons, leading to higher levels of the 
therapeutic protein to both sensory and motor nerves, which is 
probably the cause of the higher expression of IGF-I downstream 
signaling pathway like myelin proteins or GAP-43 observed in our 
model. Altogether, these data demonstrate that IGF-I delivery 
through intrathecal injection to sensory neurons with AAV1 is able 
to achieve a modest improvement of the neuropathy but not of 
nerve regeneration after injury in diabetic mice, while when driven 
by AAVrh10, IGF-I is able to significantly accelerate regeneration 
and myelination of the peripheral nerve of diabetic animals, with 
particular effect to motor neurons. These improvements may be 
relevant in diabetic animal models of longer evolution, in which 
neuropathy is more severe, and in larger species in which axonal 
regeneration through longer nerves takes more time. Despite in 
our experimental design, we did not evaluate the effect of AAVrh10 
coding for IGF-I on nerve regeneration without the effect of diabe-
tes, our results suggest that intrathecal injection of AAVrh10 could 
be a promising tool to design gene therapy approaches for dis-
eases affecting sensory and motor neurons, like DPN, as well as for 
peripheral nerve injury.
Figure 5 IGF-I signaling is enhanced in DRG of AAVrh10-treated diabetic 
mice. (a) Western blot showing phosphorylation of Ser473 Akt from DRG 
tissue extracts from animals injected with AAVrh10 coding for IGF-I or 
GFP. Total Akt was used to normalize protein levels. Western blots were 
scanned and represented as the ratio of phosphorylated Akt (pAkt) 
versus total Akt (mean ± SEM). Statistically significant differences were 
detected by Student’s t-test (*P < 0.01; n = 2 for GFP; n = 3 for IGF-I). (b) 
DRG protein extracts were immunoblotted using anti-VEGF or actin 
antibodies. Densitometries show statistically significant increase of VEGF 
in AAVrh10IGF-I–treated DRGs (values are means ± SEM and represent 
ratio of VEGF normalized by actin levels from at least two blots; n = 2 for 
GFP-treated animals and n = 5 for IGF-I–treated animals; **P < 0.01 by 
Student’s t-test). AAV, adeno-associated virus; DRG, dorsal root ganglia; 
GFP, green fluorescent protein; IGF, insulin-like growth factor; VEGF, 
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MATeRIAlS AND MeTHODS
AAV vector construction, production, and titration
GFP cDNA was cloned into HindIII and NheI sites to the plasmid pAAV-CAG-
polylinker-WPRE, containing the chicken β-actin promoter with the cyto-
megalovirus enhancer and the woodchuck hepatitis virus responsive ele-
ment (WPRE). AAV2/1 and AAV2/rh10-CAG-GFP-WPRE were generated as 
previously described48 by triple transfection in HEK 293-AAV cells (Stratagene, 
Carlsbad, CA) with branched polyethylenimine (PEI; Sigma, St Louis, MO) with 
the plasmid containing the  inverted terminal repeats of AAV2, the AAV helper 
plasmid containing Rep2 and Cap for each serotype (kindly provided by JM 
Wilson, University of Pennsylvania, PA, USA) and the pXX6 plasmid containing 
helper adenoviral genes.49 Vectors were purified by iodixanol gradients, after 
benzonase treatment48 by the Vector Production Unit at Center of Animal 
Biotechnology and Gene Therapy (Universitat Autònoma de Barcelona).
Animals
Eight to twelve-week-old male Hsd:ICR (CD-1) (Harlan Laboratories, 
Indianapolis, IN) mice were used. Mice were fed ad libitum with a standard 
diet (2018S Teklad Global; Harlan Laboratories; 17% calories from fat) and 
kept under a light–dark cycle of 12 hours (lights on at 8:00 am). To induce 
insulin-dependent diabetes, mice were given, on 5 consecutive days, an 
intraperitoneal injection of 45 mg/kg body weight of streptozotocin (dis-
solved in 0.1 mol/l citrate buffer, pH 4.5, immediately before administra-
tion). Diabetes was assessed by measuring blood glucose levels with a 
Glucometer Elite (Bayer, Leverkusen, Germany). Animal care and experi-
mental procedures were approved by the Biosafety and the Animal and 
Human Experimentation Ethical Committees of the Universitat Autònoma 
de Barcelona.
Surgical procedures
Administration of viral vectors. Animals were anesthetized by intraperitoneal 
injection of ketamine (10 mg/kg of body weight; Imalgene 500; Rhône-Mer-
ieux, Lyon, France) and xylazine (1 mg/kg of body weight; Rompun; Bayer). 
Sciatic nerve injection and injury were described previously.6 Three microliters 
of viral vectors were directly injected into the sciatic nerve using a 33-gauge 
needle and a Hamilton syringe connected to a Micropump (Micro4; World 
Precision Instruments, Sarasota, FL) at a rate of 400 nl/minute. Intrathecal ad-
ministration was performed at the lumbar region. After lateral spine exposure, 
by paravertebral muscle dissection, local anesthesia with bupivacaine 0.5% 
(B.Braun, Melsungen, Germany) was applied. Ten microliters of viral vectors 
were slowly injected into the CSF through a 33-gauge needle and a Hamilton 
syringe between lumbar vertebrae L3 and L4. Appropriate access to the intra-
thecal space was confirmed by animal’s tail movement. The needle remained 
in place at the injection site for one additional minute after which muscle and 
skin were sutured.
CSF extraction. Mice were deeply anesthetized and immobilized in stereo-
taxic appliance. An incision was made from the occipital region of the skull 
to the cervical region of the spine, and the posterior neck muscles were 
separated to access the arachnoid at the cisterna magna. Local anesthesia 
with bupivacaine was applied. An aspirator tube (Sigma-Aldrich) assembled 
to a microcapillary pipette was used to extract the CSF. A slight pressure was 
made with the microcapillary pipette on the arachnoid membrane to access 
Figure 6 AAVrh10 coding for IGF-I promotes regeneration and myelin proteins expression in injured sciatic nerves of diabetic mice. Injured sciatic nerves 
and DRG from diabetic mice treated with AAVrh10 coding for GFP or IGF-I were dissected 4 weeks after treatment. Graphs represent means ± SEM (n 
= 3–5 animals). mRNA and protein of GAP-43, a marker for nerve regeneration, are significantly increased in IGF-I–treated animals as assessed by (a) 
quantitative PCR from DRG and (b) western blot from sciatic nerve protein extracts, where levels of GAP-43 were quantified and compared to actin. 
(c) Quantitative PCR from sciatic nerve shows increased mRNA for myelin proteins P0, PMP22, MAG, and MBP in animals that received IGF-I compared 
to GFP-treated mice. (d) Protein levels of myelin protein P0 analyzed by western blot corroborated quantitative PCR results. Student’s t-tests show 
statistically significant results (***P < 0.005; **P < 0.01; *P < 0.05). AAV, adeno-associated virus; DRG, dorsal root ganglia; GAP, growth associated protein; 
GFP, green fluorescent protein; IGF, insulin-like growth factor; MBP, myelin basic protein.
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the cisterna magna. Then, 5 µl of CSF per mouse were withdrawn by aspira-
tion. Animals were euthanized just after CSF extraction.
Sciatic nerve lesion. Under anesthesia as stated above, the right sciatic nerve 
was exposed at the mid-thigh and subjected to a crush lesion during 30 sec-
onds for three times in succession with a Dumont #5 (World Precision Instru-
ments, Sarasota, FL) forceps at a constant point, 42 mm from the tip of the 
third digit. The wound was then sutured by layers.
Functional tests
Nerve conduction studies were performed bilaterally in the sciatic nerve 
at two time points, 7 and 8 weeks after induction of diabetes, correspond-
ing to 3 and 4 weeks following the surgical lesion on the right side.22 With 
animals under anesthesia (pentobarbital 40 mg/kg intraperitoneally), the 
nerve was stimulated percutaneously through a pair of small needle elec-
trodes placed first at the sciatic notch and then at the ankle. Rectangular 
electrical pulses (Grass S88) of 0.01 ms duration were applied up to 25% 
above the voltage that gave a maximal response. The compound muscle 
action potentials were recorded from the third interosseus plantar mus-
cle and from the tibialis anterior muscle with microneedle electrodes. 
Similarly, the sensory compound nerve action potential was recorded 
by electrodes placed at the fourth toe near the digital nerves. All evoked 
action potentials were displayed on a storage oscilloscope (Tektronix 420, 
Beaverton, OR) at settings appropriate to measure the amplitude from 
baseline to peak and the latency to the onset of the recorded potentials. 
The NCV was calculated for each segment tested; motor NCV for the sci-
atic notch–ankle segment and sensory NCV for the proximal segment 
sciatic notch–ankle and for the distal segment ankle–digit. During elec-
trophysiological tests, the animals were placed over a warm flat steamer 
controlled by a hot water circulating pump, and the hindpaw skin tem-
perature was maintained above 32 °C. To reduce variability between sets, 
groups of mice receiving each AAV vector encoding for GFP and IGF-1 
were studied in parallel and compared.
Quantitative real-time PCR
Sciatic nerves, DRG, and spinal cord were homogenized with Qiazol (Qiagen, 
Hilden, Germany) to obtain total RNA. Messenger RNA was retrotrans-
cribed to cDNA (Omniscript RT Kit; Qiagen), and analysis of expression 
was performed by quantitative real-time PCR (Smart Cycler II; Cepheid, 
Sunnyvale, CA) with FastStart Sybrgreen Master (Roche Diagnostics, Basel, 
Switzerland). Primer sequences used: reference gene m36B4 (forward: 
ATGGGTACAAGCGCGTCCTG; reverse: AGCCGCAAATGCAGATGGAT); IGF-I 
(forward: GGACCAGAGACCCTTTGCGG; reverse: GTGCCCTCCGAATGCTGG 
AG); P0 (forward: TCTCAGGTCACGCTCTATGTC; reverse: CAGGTAGAAGAG 
CAACAGCAG); PMP22 (forward: CTCTTGTTGGGGATCCTGTTC; reverse: AA 
GGCGGATGTGGTACAGTTC); myelin basic protein (forward: GGTGCGCCC 
AAGCGGGGC; reverse: ACTTCTGGGGCAGGGAGCC); myelin-associated 
glycoprotein (forward: AGCACAGCGTCCTGGACATC; reverse: GGCCCAGCC 
AGCTCAGCTC); and GAP-43 (forward: AGCCTAAACAAGCCGATGTGCC; 
reverse: TTCGTCTACAGCGTCTTTCTCCTCC). Amplifications were performed 
as follows: heat inactivation (5 minutes, 95 °C, 1 cycle), followed by 40 cycles 
of 95 °C, 15 seconds; 58 °C (melting temperature for each pair of primers), 
30 seconds; 72 °C, 30 seconds. Fluorescence detection of product was per-
formed at the end of the PCR extension, and melting curves were analyzed 
by monitoring the continuous decrease in fluorescence of the SYBR Green 
signal. PCR products were verified for a single amplification product using 
melting curve analysis, and the molecular weight of each product was con-
firmed by agarose electrophoresis. Quantification relative to m36B4 controls 
was calculated using the Pfaffl method.50
Histology and immunological assays
Anesthetized animals were perfused with phosphate buffer, followed by 
4% paraformaldehyde in phosphate buffer. Cryoprotected sciatic nerves, 
DRG, and spinal cord containing lumbar, thoracic, or cervical segments 
were embedded in Tissue-Tek Oct Compound (Miles, Elkhart, IN). Ten-
micrometer-thick sections of sciatic nerves and DRG and 20-µm-thick sec-
tions of spinal cord and brain were blocked and incubated with primary 
antibodies overnight at 4 °C. For sciatic nerves and DRG, the antibodies 
used were: anti-PGP 9.5 (1:500; UltraClone, Isle of Wight, UK), anti-S100 
(1:500; DakoCytomation, Glostrup, Denmark), anti-CRGP and anti-NF200 
(1:400; Sigma-Aldrich), anti-peripherin (1:400; Millipore, Billerica, MA), 
and Isolectin IB4 (1:200; Millipore). Spinal cord sections were incubated 
with the following primary antibodies: anti-APC1 (1:400; Calbiochem, 
Merck KGaA, Darmstadt, Germany), anti-glial fibrillary acidic protein 
(1:500; DakoCytomation), anti-Iba1 (1:1,000; Wako Chemicals, Richmond, 
VA), anti–choline acetyltransferase (1:50; Millipore), and anti-IGF-I (1:100; 
Abcam, Cambridge, UK). Sections were then incubated with the following 
secondary antibodies: Alexa Fluor Goat Anti-rabbit 568, Alexa Fluor Goat 
Anti-mouse 568, and Alexa Fluor Rabit Anti-goat 568 (1:200; Invitrogen, 
Carlsbad, CA). Finally, sections were counterstained with Hoescht stain 
solution (Sigma-Aldrich) for nuclei labeling, and they were mounted in Gel 
Mount (Sigma-Aldrich). Fluorescence was detected with a laser-scanning 
confocal microscope (TCs SP2; Leica Microsystems, Heidelberg, Germany), 
and images taken for quantification. For DRG neuron counting, one every 
five sections was selected, and DRG neurons were identified as large, 
round cell bodies with large round nuclei, surrounded by satellite cells 
with small elongated nuclei, and counted by two independent research-
ers. At least five sections for each DRG were used. GFP was detected by 
direct fluorescence, without antibody enhancement.
For spinal cord neuron counting, 40 µm sections separated by 200 µm 
of each spinal cord were stained with Neurotrace red fluorescent Nissl 
(Molecular Probes, Eugene, OR) following manufacturer’s instructions. GFP-
positive cells localized in the ventral horn were counted, without antibody 
enhancement, along the spinal cord to estimate the number of ventral neu-
rons transduced in each segment. For α-motoneuron counting, only cho-
line acetyltransferase–positive neurons with diameters above 20 µm, with 
a prominent nucleolus and polygonal shape in the ventral horn were con-
sidered in Nissl-stained sections. Counting was performed by two different 
researchers, and data were pooled together.
Western blot. Sciatic nerves, DRGs, and spinal cord were sonicated and ho-
mogenized in RIA lysis buffer (50 mmol/l Tris–Cl pH 7.4, 150 mmol/l NaCl, 
1 mmol/l ethylenediaminetetraacetic acid, 1% NP-40, and 0.25% sodium 
deoxycholate) and Complete Mini EDTA-free protease inhibitor cocktail 
tablets (Roche Diagnostics). Protein concentration was determined by 
BCA Protein Assay (Pierce, Rockford, IL), and 50 µg of proteins were sepa-
rated on 10% sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis gel (Bio-Rad, Hercules, CA). Polyvinylidene fluoride membranes were 
incubated with anti-VEGF (1:200; Abcam), anti-Akt-P (Ser473) (1:500; 
Cell Signaling Technology, Danvers, MA), anti-GAP-43 (1:500; Millipore) 
and anti-P0 (1:500; Abcam), and anti-rabbit conjugated to horseradish 
peroxidase (1:2,000; DakoCytomation) combined with western blotting 
detection reagent (ECL Plus; Amersham, Freiburg, Germany) according 
to the manufacturer’s instructions. The same membranes were stripped 
and incubated with anti-actin (1:500; Sigma-Aldrich) and anti-total Akt 
(1:500; Cell Signaling Technology). Band pixel intensities were quantified 
by GeneSnap software for Gene Genius Bio Imaging System (Syngene, 
Cambridge, UK) and normalized by anti-actin levels in each line and by 
anti-total Akt levels for Akt-P samples.
Statistics
Values are represented as mean ± SEM. Statistical analyses using Student’s 
t-test or one- and two-way analysis of variance with Bonferroni or Tukey post 
hoc tests were performed for each set of data. Differences were considered 
statistically significant if P < 0.05.
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